BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, announces the initiation of the clinical batches production of Livatag (doxorubicin Transdrug) for its Phase 3 clinical trial in primary liver cancer.
This production will be performed by qualified companies for injectable cytotoxic products in nanoparticle form. The BioAlliance Pharma’s team specialized in industrial development, who previously performed scale up of the technology, will collaborate with its partners throughout the process to ensure the transmission of its know-how specific to nanoparticle Transdrug technology.
The production of clinical trial batches is one of the milestones of Livatag Phase 3 clinical trial in primary liver cancer, last development step of the product.
The Company has enlarged the protection of its Transdrug technology with the grant of a second European patent. This strengthens the industrial property of Livatag and completes the market exclusivity given by the orphan status, thus reinforcing the value of this key asset for the Company.
“The BioAlliance Pharma’s industrial development team and its European partners have been fully committed to prepare the clinical production of Livatag®, relying on their specific nanotechnology expertise and know-how”, declares Judith Greciet, CEO of BioAlliance Pharma.
Date: August 1, 2011
Source: BioAlliance Pharma SA
Filed Under: Drug Discovery